Developer docs
API playgroundTry for free, no card

Search company profiles

Kytopen

Full company profile

uuid0000gvq

Namestring
Kytopen
Legal namestring
Kytopen Corp.
Websiteurl
kytopen.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Kytopen is a private biotechnology tools company founded in 2017 as an MIT spinout, headquartered in Cambridge, Massachusetts with an R&D site in Louisville, Colorado. The company develops the Flowfect® platform, a non-viral gene delivery system that combines continuous fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP to primary cells. The platform is offered in two primary instruments: Flowfect Discover™, an automated small-volume high-throughput system capable of running up to 96 transfection conditions in approximately 10 minutes for discovery and process optimization, and Flowfect Tx®, a closed-system GMP-compatible instrument for clinical and commercial manufacturing that processes billions of cells per minute. Proprietary consumables — Flowfect Tx Uni Cartridge, Flowfect Discover Tips, and Flowfect Uni and Omni Buffers — accompany the instruments and create a recurring revenue stream.

Kytopen sells and supports the Flowfect platform through a direct enterprise sales motion targeting biopharmaceutical companies developing CAR-T, NK cell, stem cell, and emerging modalities; CDMOs providing process development and manufacturing services; and academic translational medical centers conducting discovery research. The company also operates a structured six-month Technology Access Program (TAP) in which partners receive a Flowfect Tx system and hands-on support from Kytopen's field applications team to move therapeutics from proof-of-concept through process development and clinical manufacturing. Pricing is quote-based and not publicly disclosed; products are offered as Research Use Only (RUO) with GMP-grade configurations available for clinical manufacturing. The Flowfect Tx system has a Drug Master File on file with the U.S. FDA, and Kytopen has established technology access agreements and CDMO channel partnerships with organizations including BioCentriq, Charles River Laboratories, Mirus Bio, RoosterBio, Excellos, T-CURX, Fraunhofer IZI, TQ Therapeutics, and BlueWhale Bio.

The company has raised approximately $36.6 million in disclosed equity funding (a $3.6M seed led by The Engine in 2019, a $30M Series A led by Northpond Ventures in 2021, and an undisclosed Series B led by Telegraph Hill Partners announced April 2026), supplemented by NIH SBIR and NSF grants. As of the available data, Kytopen operates with 11–50 employees under the leadership of CEO Michael Chiu, Ph.D. (appointed August 2023) and Chief Commercial Officer Kevin Gutshall (appointed April 2024), with a Scientific Advisory Board of seven leading academic researchers from MIT, Caltech, Stanford, Rice, Boston University, and Northeastern University.

Short descriptiontext

Kytopen is an MIT spinout developing the Flowfect® platform, a non-viral electro-mechanical continuous-flow gene delivery system that enables high-throughput cell therapy discovery and GMP-scale manufacturing of engineered cell therapies for biopharmaceutical companies, CDMOs, and academic medical centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
non-viral gene delivery, cell therapy manufacturing, electroporation instruments, genome engineering platform, cell transfection technology
Industry2 codes
PRIMARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • Analytical Laboratory Instrument Manufacturing334516
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cell Therapy Manufacturing Equipment
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Flowfect® Platform Sales and Service
TypeHardware Sales
Description

Kytopen sells and supports its Flowfect Discover™ and Flowfect Tx™ instruments and associated consumables (Flowfect Tx™ Uni Cartridge, Flowfect Discover™ Tips, and Flowfect® Uni and Omni Buffers) to biopharmaceutical companies, CDMOs, and academic medical centers. The company also generates revenue through its Technology Access Program (TAP) which provides partners with a manufacturing system and hands-on field applications support.

kytopen.com
2Technology Access Program (TAP)
TypeProfessional Services
Description

TAP is a structured six-month engagement in which Kytopen works closely with partners to validate technical needs on the Flowfect platform, transfer processes, and optimize workflows for manufacturing scale. Partners pay for access to the platform, applications support, and process development services, moving therapeutics from proof-of-concept through clinical and commercial manufacturing.

kytopen.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Flowfect
Description

Non-viral gene delivery platform combining continuous fluid flow with electric fields for high-efficiency delivery of payloads such as mRNA, DNA, and CRISPR Cas9 RNP to cells.

kytopen.com
+3 more records
Core offering1 text field

Kytopen develops and sells the Flowfect® non-viral gene delivery platform — instruments and proprietary consumables that combine continuous fluid flow with electric fields to deliver mRNA, DNA, and CRISPR Cas9 RNP into primary cells. The platform spans two instruments: Flowfect Discover™ for automated high-throughput small-volume optimization and Flowfect Tx® for closed-system large-scale GMP-compatible manufacturing, supported by the Technology Access Program (TAP) service engagement.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Reduces cell therapy manufacturing time from weeks to days
+5 more records
Product overview1 text field

Kytopen offers the Flowfect® platform, a non-viral gene delivery system that combines continuous fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP to cells. The platform consists of two instrument products — Flowfect Discover™ for small-volume, high-throughput discovery and optimization (96-well format, up to 96 conditions in ~10–15 minutes), and Flowfect Tx® for large-scale clinical and commercial manufacturing (billions of cells in minutes, available in both RUO and GMP versions) — supported by a portfolio of proprietary consumables including the Flowfect Tx® Uni Cartridge, Flowfect Discover™ Tips, and Flowfect® Uni and Omni Buffers. The platform is designed for predictive scaling: parameters optimized on Flowfect Discover™ translate directly to Flowfect Tx® manufacturing runs, enabling a single technology to span discovery through GMP production.

Product and service6 records
1Flowfect Discover™ Platform
CategoryInstrument (Discovery & Optimization)
Description

Automated small-volume liquid-handling platform that performs high-throughput transfections for drug discovery, screening, and process optimization, using continuous flow transfection to retain cell functionality. Runs up to 96 separate conditions in a single run of approximately 10 minutes for sample volumes ranging from 50–100 µL, compatible with standard liquid handling consumables such as HSP9655 96-well plates. For research use only.

2Flowfect Tx® Platform
CategoryInstrument (Manufacturing)
Description

Closed-system transfection instrument that enables large-scale payload delivery to billions of cells within minutes, processing 10–50 million cells per mL at 25–50 mL per minute with no batch volume limitations. Compatible with standard cell therapy and off-the-shelf bioprocessing bags, and available in both Research Use Only (RUO) and GMP-grade versions for clinical manufacturing.

3Flowfect Tx® Uni Cartridge
CategoryConsumable
Description

Single-use cartridge companion to the Flowfect Tx® platform, supporting large-scale transfection workflows.

4Flowfect Discover™ Tips
CategoryConsumable
Description

Specialized pipette tips designed for use with the Flowfect Discover™ platform.

5Flowfect® Uni and Omni Buffers
CategoryConsumable
Description

Proprietary buffer solutions (Uni and Omni variants) that accompany Kytopen's Flowfect® devices to support transfection workflows.

6Technology Access Program (TAP)
CategoryService Program
Description

Structured six-month engagement in which Kytopen works closely with partners to validate technical needs on the Flowfect platform, transfer processes, and optimize workflows for manufacturing scale, including hands-on field applications support for clinical and commercial manufacturing of cell therapies.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

Kytopen entered a technology access agreement with T-CURX (initially February 2025, expanded April 2026) to provide access to its Flowfect Tx® cellular engineering platform. The expanded partnership integrates Kytopen's continuous-flow transfection technology with T-CURX's proprietary transposon-based gene transfer system.

2Fraunhofer IZI
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

Fraunhofer Institute for Cell Therapy and Immunology (IZI) joined Kytopen and T-CURX to establish a joint Center of Excellence for advanced non-viral cell therapies. Fraunhofer IZI leads process development and manufacturing scale-up efforts in Germany for the partnership.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-02
Description

Kytopen expanded its partnership with TQ Therapeutics through a technology access agreement, providing access to its Flowfect Tx® cellular engineering platform to support TQ's development of in vivo cell therapies. The collaboration integrates Kytopen's technology into TQ's CELLfinity platform for autologous mRNA T-cell therapies.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-12
Description

Kytopen and Excellos announced a collaboration to develop scalable, non-viral cell therapy manufacturing technologies, focusing on the compatibility of Kytopen's Flowfect Tx® platform with Excellos' donor-to-dose manufacturing model. The joint effort aims to improve process consistency, scalability, and cell quality.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-09-09
Description

Kytopen and BlueWhale Bio joined forces to develop a non-viral cell therapy manufacturing workflow, combining their respective technologies and expertise.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-05-08
Description

Kytopen and Bio-Techne collaborated on an integrated cellular engineering workflow to expedite cell therapy manufacturing by combining Kytopen's Flowfect® platform with Bio-Techne's cellular analysis and reagent products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-08-13
Description

Charles River Laboratories was commissioned by Kytopen to conduct in vivo preclinical studies validating large-scale production and enhanced efficacy of Flowfect™ engineered-NK cell therapies under the NIH Phase II SBIR award. Charles River also completed a comparative study demonstrating Flowfect Tx™ outperforms conventional electroporation platforms in primary T-cell editing.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-03-26
Description

RoosterBio collaborated with Kytopen to develop exosome loading applications using Flowfect® technology for mesenchymal stem/stromal cell (MSC)-derived extracellular vesicles with potential broad utility for advanced therapy developers.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-09-19
Description

Kytopen partnered with Ganymede Bio to integrate its Lab-as-Code™ cloud data platform with Kytopen's Flowfect Discover™ and Flowfect Tx™ instruments. The integration enables FAIR-compliant structured data from Flowfect instruments to be published directly to the cloud, integrating with customer ELNs, LIMS, and data pipelines for automated data management.

10Omid Veiseh Laboratory (Rice University)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-11
Description

Kytopen collaborated with the Omid Veiseh Laboratory at Rice University to place both Flowfect Discover™ and Flowfect Tx™ platforms at the translational medical research lab. The collaboration drives cutting-edge genome engineering research and expedites discovery of novel cell therapies for cancer, autoimmunity, metabolic regulation, wound healing, and infectious diseases.

kytopen.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-31
Description

Kytopen partnered with Mirus Bio, a pioneering transfection reagent company with over 25 years of experience, to combine Mirus Bio's nucleic acid delivery chemistry expertise with Kytopen's electro-mechanical continuous transfection technology. The collaboration aims to enable scalable genome engineering with complex payloads to traditionally difficult-to-manipulate primary cell types while improving production yields.

12Paul K. Wotton, Ph.D.
Strategic tierCoreTypeOthersAnnounced on2023-01-09
Description

Paul K. Wotton, Ph.D. (former CEO of Obsidian Therapeutics, board member of Vericel Corporation and Cynata Therapeutics) was appointed Chair of Kytopen's Board of Directors, bringing 35 years of experience building private and public biopharmaceutical companies.

kytopen.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-23
Description

BioCentriq, a cell and gene therapy CDMO (purchased by GC of South Korea for $73M), partnered with Kytopen to test and validate Flowfect® technology for T-cell transfection. The partnership was extended in 2023 to include the Flowfect Discover™ platform for rapid optimization prior to manufacturing scale-up. BioCentriq serves as a preferred development and manufacturing partner for developers using Kytopen's technology.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

MaxCyte is the leading commercial-scale electroporation platform for cell therapy manufacturing, offering the ExPERT™ flow electroporation systems used by virtually all major CAR-T developers. It is the most direct competitor to Kytopen's Flowfect Tx™ in non-viral gene delivery for clinical and commercial cell therapy manufacturing.

TypeBroad incumbent
Description

Lonza is a global CDMO and life sciences tools provider whose Nucleofector™ platform is a foundational non-viral transfection technology widely used in cell therapy research and process development. As a broad incumbent with deep CDMO relationships, Lonza competes with Kytopen across the cell therapy workflow and could bundle transfection with manufacturing services.

TypeBroad incumbent
Description

Thermo Fisher's Gibco CTS Xenon™ Electroporation System is a major electroporation platform targeted at cell therapy manufacturing. As a broad life sciences incumbent with massive distribution, Thermo Fisher competes head-to-head with Flowfect Tx™ and benefits from bundled reagent, instrument, and service offerings.

TypeEmerging player
Description

CellFE is a private biotech tool company developing a microfluidics-based rapid transfection platform for cell therapy manufacturing. It is a direct emerging competitor to Kytopen's Flowfect technology, targeting similar non-viral gene delivery applications; notably, Kytopen's CCO Kevin Gutshall previously served as CellFE's Chief Business Officer.

TypeEmerging player
Description

Celetrix manufactures electroporation devices and reagents used in cell therapy and gene editing research and manufacturing. It is a niche emerging competitor in non-viral gene delivery, with overlapping customer base in academic and early-stage commercial cell therapy developers.

TypeOthers
Description

Mirus Bio is a leading nucleic acid delivery reagent company (now part of Roche) with deep expertise in transfection chemistry. It is a strategic partner of Kytopen (combining Mirus chemistry with Flowfect hardware) and also a partial competitor via its standalone reagent offerings for viral and non-viral delivery.

TypeOthers
Description

Bio-Techne is a major life sciences reagent and analytical tools provider with deep presence in cell therapy and gene editing workflows. It is both a strategic partner of Kytopen (integrated workflow collaboration) and a broad incumbent whose reagents and analytical platforms are adjacent to Flowfect's gene delivery value chain.

TypeRegional player
Description

BioCentriq is a U.S.-based cell and gene therapy CDMO (acquired by GC of South Korea) that has adopted Kytopen's Flowfect technology and serves as a preferred development and manufacturing partner. It is a customer and channel influencer rather than a direct competitor, but its adoption of Flowfect sets a competitive benchmark for other CDMOs.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kytopen

Cell Therapy Manufacturing Equipmentkytopen.com

Kytopen is an MIT spinout developing the Flowfect® platform, a non-viral electro-mechanical continuous-flow gene delivery system that enables high-throughput cell therapy discovery and GMP-scale manufacturing of engineered cell therapies for biopharmaceutical companies, CDMOs, and academic medical centers.

What Kytopen does

Kytopen is a private biotechnology tools company founded in 2017 as an MIT spinout, headquartered in Cambridge, Massachusetts with an R&D site in Louisville, Colorado. The company develops the Flowfect® platform, a non-viral gene delivery system that combines continuous fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP to primary cells. The platform is offered in two primary instruments: Flowfect Discover™, an automated small-volume high-throughput system capable of running up to 96 transfection conditions in approximately 10 minutes for discovery and process optimization, and Flowfect Tx®, a closed-system GMP-compatible instrument for clinical and commercial manufacturing that processes billions of cells per minute. Proprietary consumables — Flowfect Tx Uni Cartridge, Flowfect Discover Tips, and Flowfect Uni and Omni Buffers — accompany the instruments and create a recurring revenue stream.

Kytopen sells and supports the Flowfect platform through a direct enterprise sales motion targeting biopharmaceutical companies developing CAR-T, NK cell, stem cell, and emerging modalities; CDMOs providing process development and manufacturing services; and academic translational medical centers conducting discovery research. The company also operates a structured six-month Technology Access Program (TAP) in which partners receive a Flowfect Tx system and hands-on support from Kytopen's field applications team to move therapeutics from proof-of-concept through process development and clinical manufacturing. Pricing is quote-based and not publicly disclosed; products are offered as Research Use Only (RUO) with GMP-grade configurations available for clinical manufacturing. The Flowfect Tx system has a Drug Master File on file with the U.S. FDA, and Kytopen has established technology access agreements and CDMO channel partnerships with organizations including BioCentriq, Charles River Laboratories, Mirus Bio, RoosterBio, Excellos, T-CURX, Fraunhofer IZI, TQ Therapeutics, and BlueWhale Bio.

The company has raised approximately $36.6 million in disclosed equity funding (a $3.6M seed led by The Engine in 2019, a $30M Series A led by Northpond Ventures in 2021, and an undisclosed Series B led by Telegraph Hill Partners announced April 2026), supplemented by NIH SBIR and NSF grants. As of the available data, Kytopen operates with 11–50 employees under the leadership of CEO Michael Chiu, Ph.D. (appointed August 2023) and Chief Commercial Officer Kevin Gutshall (appointed April 2024), with a Scientific Advisory Board of seven leading academic researchers from MIT, Caltech, Stanford, Rice, Boston University, and Northeastern University.

Kytopen firmographics

Firmographics
Name
Kytopen
Legal name
Kytopen Corp.
Website
https://kytopen.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Kytopen is an MIT spinout developing the Flowfect® platform, a non-viral electro-mechanical continuous-flow gene delivery system that enables high-throughput cell therapy discovery and GMP-scale manufacturing of engineered cell therapies for biopharmaceutical companies, CDMOs, and academic medical centers.
Ownership category
akta.pro rank

Kytopen industry classification

Industry
Product category
Cell Therapy Manufacturing Equipment
NAICS
Analytical Laboratory Instrument Manufacturing (334516)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAHAAAN
Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Non-viral gene delivery
  • Cell therapy manufacturing
  • Electroporation instruments
  • Genome engineering platform
  • Cell transfection technology

Where Kytopen is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Kytopen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Flowfect® Platform Sales and Service: Kytopen sells and supports its Flowfect Discover™ and Flowfect Tx™ instruments and associated consumables (Flowfect Tx™ Uni Cartridge, Flowfect Discover™ Tips, and Flowfect® Uni and Omni Buffers) to biopharmaceutical companies, CDMOs, and academic medical centers. The company also generates revenue through its Technology Access Program (TAP) which provides partners with a manufacturing system and hands-on field applications support.
  2. Technology Access Program (TAP): TAP is a structured six-month engagement in which Kytopen works closely with partners to validate technical needs on the Flowfect platform, transfer processes, and optimize workflows for manufacturing scale. Partners pay for access to the platform, applications support, and process development services, moving therapeutics from proof-of-concept through clinical and commercial manufacturing.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Kytopen product offering

Product offering

Core offering

Kytopen develops and sells the Flowfect® non-viral gene delivery platform — instruments and proprietary consumables that combine continuous fluid flow with electric fields to deliver mRNA, DNA, and CRISPR Cas9 RNP into primary cells. The platform spans two instruments: Flowfect Discover™ for automated high-throughput small-volume optimization and Flowfect Tx® for closed-system large-scale GMP-compatible manufacturing, supported by the Technology Access Program (TAP) service engagement.

Product overview

Kytopen offers the Flowfect® platform, a non-viral gene delivery system that combines continuous fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP to cells. The platform consists of two instrument products — Flowfect Discover™ for small-volume, high-throughput discovery and optimization (96-well format, up to 96 conditions in ~10–15 minutes), and Flowfect Tx® for large-scale clinical and commercial manufacturing (billions of cells in minutes, available in both RUO and GMP versions) — supported by a portfolio of proprietary consumables including the Flowfect Tx® Uni Cartridge, Flowfect Discover™ Tips, and Flowfect® Uni and Omni Buffers. The platform is designed for predictive scaling: parameters optimized on Flowfect Discover™ translate directly to Flowfect Tx® manufacturing runs, enabling a single technology to span discovery through GMP production.

Differentiator

Problem solved

Functional benefit

Brands

  • Flowfect: Non-viral gene delivery platform combining continuous fluid flow with electric fields for high-efficiency delivery of payloads such as mRNA, DNA, and CRISPR Cas9 RNP to cells.
  • Flowfect Discover
  • Flowfect Tx
  • Technology Access Program (TAP)

Products and services

  • Flowfect Discover™ Platform Automated small-volume liquid-handling platform that performs high-throughput transfections for drug discovery, screening, and process optimization, using continuous flow transfection to retain cell functionality. Runs up to 96 separate conditions in a single run of approximately 10 minutes for sample volumes ranging from 50–100 µL, compatible with standard liquid handling consumables such as HSP9655 96-well plates. For research use only.
  • Flowfect Tx® Platform Closed-system transfection instrument that enables large-scale payload delivery to billions of cells within minutes, processing 10–50 million cells per mL at 25–50 mL per minute with no batch volume limitations. Compatible with standard cell therapy and off-the-shelf bioprocessing bags, and available in both Research Use Only (RUO) and GMP-grade versions for clinical manufacturing.
  • Flowfect Tx® Uni Cartridge Single-use cartridge companion to the Flowfect Tx® platform, supporting large-scale transfection workflows.
  • Flowfect Discover™ Tips Specialized pipette tips designed for use with the Flowfect Discover™ platform.
  • Flowfect® Uni and Omni Buffers Proprietary buffer solutions (Uni and Omni variants) that accompany Kytopen's Flowfect® devices to support transfection workflows.
  • Technology Access Program (TAP) Structured six-month engagement in which Kytopen works closely with partners to validate technical needs on the Flowfect platform, transfer processes, and optimize workflows for manufacturing scale, including hands-on field applications support for clinical and commercial manufacturing of cell therapies.

Quantifiable outcome

  • Reduces cell therapy manufacturing time from weeks to days
  • +5 more outcomes

Companies that use Kytopen

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Kytopen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Kytopen partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • T-CURXcoreStrategic or Co-development Partner · 29 April 2026Kytopen entered a technology access agreement with T-CURX (initially February 2025, expanded April 2026) to provide access to its Flowfect Tx® cellular engineering platform. The expanded partnership integrates Kytopen's continuous-flow transfection technology with T-CURX's proprietary transposon-based gene transfer system.
  • Fraunhofer IZIcoreStrategic or Co-development Partner · 29 April 2026Fraunhofer Institute for Cell Therapy and Immunology (IZI) joined Kytopen and T-CURX to establish a joint Center of Excellence for advanced non-viral cell therapies. Fraunhofer IZI leads process development and manufacturing scale-up efforts in Germany for the partnership.
  • TQ TherapeuticscoreStrategic or Co-development Partner · 2 December 2025Kytopen expanded its partnership with TQ Therapeutics through a technology access agreement, providing access to its Flowfect Tx® cellular engineering platform to support TQ's development of in vivo cell therapies. The collaboration integrates Kytopen's technology into TQ's CELLfinity platform for autologous mRNA T-cell therapies.
  • ExcellosminorStrategic or Co-development Partner · 12 November 2025Kytopen and Excellos announced a collaboration to develop scalable, non-viral cell therapy manufacturing technologies, focusing on the compatibility of Kytopen's Flowfect Tx® platform with Excellos' donor-to-dose manufacturing model. The joint effort aims to improve process consistency, scalability, and cell quality.
  • BlueWhale BiominorStrategic or Co-development Partner · 9 September 2025Kytopen and BlueWhale Bio joined forces to develop a non-viral cell therapy manufacturing workflow, combining their respective technologies and expertise.
  • Bio-TechneminorStrategic or Co-development Partner · 8 May 2025Kytopen and Bio-Techne collaborated on an integrated cellular engineering workflow to expedite cell therapy manufacturing by combining Kytopen's Flowfect® platform with Bio-Techne's cellular analysis and reagent products.
  • Charles River LaboratoriescoreStrategic or Co-development Partner · 13 August 2024Charles River Laboratories was commissioned by Kytopen to conduct in vivo preclinical studies validating large-scale production and enhanced efficacy of Flowfect™ engineered-NK cell therapies under the NIH Phase II SBIR award. Charles River also completed a comparative study demonstrating Flowfect Tx™ outperforms conventional electroporation platforms in primary T-cell editing.
  • RoosterBiominorStrategic or Co-development Partner · 26 March 2024RoosterBio collaborated with Kytopen to develop exosome loading applications using Flowfect® technology for mesenchymal stem/stromal cell (MSC)-derived extracellular vesicles with potential broad utility for advanced therapy developers.
  • Ganymede BiocoreTechnology or Integration · 19 September 2023Kytopen partnered with Ganymede Bio to integrate its Lab-as-Code™ cloud data platform with Kytopen's Flowfect Discover™ and Flowfect Tx™ instruments. The integration enables FAIR-compliant structured data from Flowfect instruments to be published directly to the cloud, integrating with customer ELNs, LIMS, and data pipelines for automated data management.
  • Omid Veiseh Laboratory (Rice University)coreStrategic or Co-development Partner · 11 July 2023Kytopen collaborated with the Omid Veiseh Laboratory at Rice University to place both Flowfect Discover™ and Flowfect Tx™ platforms at the translational medical research lab. The collaboration drives cutting-edge genome engineering research and expedites discovery of novel cell therapies for cancer, autoimmunity, metabolic regulation, wound healing, and infectious diseases.
  • Mirus BiocoreStrategic or Co-development Partner · 31 January 2023Kytopen partnered with Mirus Bio, a pioneering transfection reagent company with over 25 years of experience, to combine Mirus Bio's nucleic acid delivery chemistry expertise with Kytopen's electro-mechanical continuous transfection technology. The collaboration aims to enable scalable genome engineering with complex payloads to traditionally difficult-to-manipulate primary cell types while improving production yields.
  • Paul K. Wotton, Ph.D.coreOthers · 9 January 2023Paul K. Wotton, Ph.D. (former CEO of Obsidian Therapeutics, board member of Vericel Corporation and Cynata Therapeutics) was appointed Chair of Kytopen's Board of Directors, bringing 35 years of experience building private and public biopharmaceutical companies.
  • BioCentriqcoreStrategic or Co-development Partner · 23 March 2021BioCentriq, a cell and gene therapy CDMO (purchased by GC of South Korea for $73M), partnered with Kytopen to test and validate Flowfect® technology for T-cell transfection. The partnership was extended in 2023 to include the Flowfect Discover™ platform for rapid optimization prior to manufacturing scale-up. BioCentriq serves as a preferred development and manufacturing partner for developers using Kytopen's technology.

Scale indicators13 records

Recent moves2 records

Expansion highlights6 records

Kytopen competitors and assessment

Company assessment

Direct peers

  • MaxCyte: MaxCyte is the leading commercial-scale electroporation platform for cell therapy manufacturing, offering the ExPERT™ flow electroporation systems used by virtually all major CAR-T developers. It is the most direct competitor to Kytopen's Flowfect Tx™ in non-viral gene delivery for clinical and commercial cell therapy manufacturing.

Broad incumbents

  • Lonza (Nucleofector): Lonza is a global CDMO and life sciences tools provider whose Nucleofector™ platform is a foundational non-viral transfection technology widely used in cell therapy research and process development. As a broad incumbent with deep CDMO relationships, Lonza competes with Kytopen across the cell therapy workflow and could bundle transfection with manufacturing services.
  • Thermo Fisher Scientific (CTS Xenon): Thermo Fisher's Gibco CTS Xenon™ Electroporation System is a major electroporation platform targeted at cell therapy manufacturing. As a broad life sciences incumbent with massive distribution, Thermo Fisher competes head-to-head with Flowfect Tx™ and benefits from bundled reagent, instrument, and service offerings.

Emerging players

  • CellFE: CellFE is a private biotech tool company developing a microfluidics-based rapid transfection platform for cell therapy manufacturing. It is a direct emerging competitor to Kytopen's Flowfect technology, targeting similar non-viral gene delivery applications; notably, Kytopen's CCO Kevin Gutshall previously served as CellFE's Chief Business Officer.
  • Celetrix: Celetrix manufactures electroporation devices and reagents used in cell therapy and gene editing research and manufacturing. It is a niche emerging competitor in non-viral gene delivery, with overlapping customer base in academic and early-stage commercial cell therapy developers.

Others

  • Mirus Bio: Mirus Bio is a leading nucleic acid delivery reagent company (now part of Roche) with deep expertise in transfection chemistry. It is a strategic partner of Kytopen (combining Mirus chemistry with Flowfect hardware) and also a partial competitor via its standalone reagent offerings for viral and non-viral delivery.
  • Bio-Techne: Bio-Techne is a major life sciences reagent and analytical tools provider with deep presence in cell therapy and gene editing workflows. It is both a strategic partner of Kytopen (integrated workflow collaboration) and a broad incumbent whose reagents and analytical platforms are adjacent to Flowfect's gene delivery value chain.

Regional players

  • BioCentriq: BioCentriq is a U.S.-based cell and gene therapy CDMO (acquired by GC of South Korea) that has adopted Kytopen's Flowfect technology and serves as a preferred development and manufacturing partner. It is a customer and channel influencer rather than a direct competitor, but its adoption of Flowfect sets a competitive benchmark for other CDMOs.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Kytopen social profiles

Digital presence

Kytopen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kytopen leadership team

Management profile

Number of profiles

Profiles15 records

Kytopen funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kytopen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kytopen

What does Kytopen do?

Kytopen develops and sells the Flowfect® non-viral gene delivery platform — instruments and proprietary consumables that combine continuous fluid flow with electric fields to deliver mRNA, DNA, and CRISPR Cas9 RNP into primary cells. The platform spans two instruments: Flowfect Discover™ for automated high-throughput small-volume optimization and Flowfect Tx® for closed-system large-scale GMP-compatible manufacturing, supported by the Technology Access Program (TAP) service engagement.

Is Kytopen a public or private company?

Kytopen is a private company. It is classified as venture growth investor backed and is currently operating.

When was Kytopen founded?

Kytopen was founded in 2017. It employs 11 to 50 people.

Where is Kytopen based?

Kytopen is headquartered in Cambridge, United States, in the North America region.

How does Kytopen make money?

Two revenue lines are on record. Flowfect® Platform Sales and Service is the primary driver. The others are technology Access Program (TAP).

Who are Kytopen's main competitors?

MaxCyte is listed as a direct peer. Broad incumbents are Lonza (Nucleofector) and Thermo Fisher Scientific (CTS Xenon). Emerging players are CellFE and Celetrix. Others are Mirus Bio and Bio-Techne. BioCentriq is listed as a regional player.

Does Kytopen have an API?

No public API is recorded for Kytopen.

What industry is Kytopen in?

Kytopen's product category is Cell Therapy Manufacturing Equipment. Its primary akta.pro industry code is HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods), with a secondary code of HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics). Its NAICS code is 334516 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireKytopen, T-CURX, and the Fraunhofer IZI Establish Center of Excellence to Develop Advanced, Non-viral Cell TherapiesKytopen, T-CURX, and Fraunhofer IZI have established a joint Center of Excellence to develop advanced non-viral cell therapies, combining their respective technologies and expertise. The CoE integrates Kytopen's Flowfect® continuous-flow transfection technology with T-CURX's proprietary transposon-based gene transfer system, with process development and manufacturing scale-up led by Fraunhofer IZI teams in Germany. The partnership aims to address key bottlenecks in cell therapy manufacturing, accelerate development timelines, and improve the cost-effectiveness and accessibility of engineered cell therapies globally.Pulse 2.0Kytopen: Series B Investment To Scale Cell Therapy Manufacturing PlatformKytopen announced the close of a Series B financing round led by Telegraph Hill Partners, with the investor joining the company's board of directors as part of the deal. The funding will support global expansion across the U.S. and Europe along with commercialization of Kytopen's Flowfect® non-viral, continuous flow cellular engineering platform. The technology integrates mechanical, electrical, and chemical forces to enable large-scale cell modification for manufacturing cell therapies.KytopenKytopen Expands Commercialization Efforts and Board of Directors Following Series B Investment Led by Telegraph Hill PartnersKytopen Corp., a Cambridge-based cellular engineering company, announced Series B financing led by Telegraph Hill Partners with participation from existing investors. The funding will accelerate global commercial expansion and drive adoption of its Flowfect® technology platform across the U.S. and Europe. The company's continuous flow transfection technology enables rapid engineering of therapeutic cells with improved cell health and lower costs compared to existing methods.FinSMEsKytopen Closes Series B FundingKytopen Corp., a Cambridge, Massachusetts-based company specializing in non-viral, continuous flow cellular engineering solutions, has closed a Series B funding round led by Telegraph Hill Partners. As part of the investment, Telegraph Hill Partners will join Kytopen's Board of Directors. The company plans to use the proceeds to accelerate global commercial expansion and drive adoption of its Flowfect technology platform across the U.S. and Europe, while advancing new cell therapies through strategic partnerships.PR NewswireKytopen Announces Collaboration with BlueWhale Bio to Revolutionize Cell Therapy ManufacturingKytopen and BlueWhale Bio announced a collaboration to develop a non-viral cell therapy manufacturing workflow. BlueWhale's Synecta CDNPs mimic T-cell priming, while Kytopen's Flowfect technology processes billions of cells in minutes. The partnership aims to reduce vein-to-vein times and lower costs for personalized cell therapies.PR NewswireKytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering WorkflowKytopen and Aldevron have announced a collaboration to enhance cell therapy manufacturing using their respective technologies, focusing on CRISPR-mediated T-cell engineering. The partnership aims to increase yields and streamline workflows, with data to be presented at the ISCT Annual Meeting in May 2025. This collaboration supports the development of scalable, high-quality cell therapies for clinical and commercial use.PR NewswireKytopen Receives Prestigious Phase II SBIR Award of $1.6M from the NIAID/NIH to Support Pivotal In Vivo Studies of Engineered Natural Killer CellsKytopen Corp. has received a $1.6 million Phase II SBIR Fast-Track grant from the National Institutes of Health to fund in vivo preclinical studies for its engineered Natural Killer cell therapies. The company will commission Charles River Laboratories to conduct these studies to validate the large-scale production and enhanced efficacy of its Flowfect™ technology.KytopenKytopen Receives Prestigious Phase II SBIR Award of $1.6M from the NIAID/NIH to Support Pivotal In Vivo Studies of Engineered Natural Killer CellsKytopen Corp. received a $1.6 million Phase II SBIR Fast-Track grant from the National Institutes of Health to conduct in vivo preclinical studies on its Flowfect™ engineered NK cell therapies. The company will commission Charles River Laboratories to perform these studies, which aim to validate large-scale production and enhanced efficacy for next-generation cell therapy solutions.PR NewswireKytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial OfficerKytopen Corp. announced the appointment of Kevin Gutshall as Chief Commercial Officer, effective April 1, 2024, to lead commercialization and marketing efforts for its Flowfect platforms. This executive hire is part of Kytopen's strategic plan to build commercial operations and deploy its Flowfect Tx™ manufacturing platform amid market growth in advanced therapeutic medicines.PR NewswireKytopen Announces Launch of Technology Access Program Supported by an Expanded Applications TeamKytopen Corp. announced the launch of its Flowfect® Technology Access Program (TAP), providing therapeutic partners with Flowfect Tx™ manufacturing systems and hands-on field applications support to advance therapeutics from proof-of-concept through clinical and commercial production. The company expanded its process development and applications team by hiring researchers from Artisan Bio and closed a financing round in January led by Northpond Ventures to support this commercial expansion. Kytopen, headquartered in Cambridge, Massachusetts with an R&D site in Denver, Colorado, will present the program at upcoming industry conferences in Rome and San Diego.